To prospectively assess the efficacy and safety of conteltinib at RP2Ds, a multicenter, single-arm phase 2 study in ALK-positive, crizotinib-refractory NSCLC patients (CTR20181770) and a randomized phase 3 study of conteltinib versus crizotinib in patients with ALK TKI-naïve, advanced ALK-positive NSCLC (CTR20200770) are ongoing. Here, ALK is linked to non-small cell lung carcinoma.